PRESS RELEASE | PORCHEVILLE, FRANCE – FEBRUARY 29, 2024
GenEvolutioN has introduced a new miniaturized Cell Transformation Assay (CTA) with fluorescent labelling, offering a reliable alternative for identifying non-genotoxic carcinogens in Food Contact Material (FCM) extracts.
Advancing Carcinogenicity Testing
Cell Transformation Assays (CTAs) are designed to predict the carcinogenic potential of chemicals by evaluating their effects on specific cell types. This process assesses how normal cells may transform into malignant ones, a critical step in identifying hazardous substances.
The test is conducted using Bhas 42 cells, a 3T3 mouse fibroblast cell line transfected with Ras genes, enabling the observation of transformation through key indicators such as:
- Basophilic staining
- Spindle-shaped cells
- Multilayer growth
- Random cell orientation
- Invasive cell growth
Why It Matters – Non-Intentionally Added Substances (NIAS) in Food Contact Materials
Non-Intentionally Added Substances (NIAS) are chemical compounds present in food contact materials (FCMs) that can migrate into food. While not added for a technical reason, these substances pose potential safety concerns and require rigorous evaluation.
GenEvolutioN’s Innovations in CTA Testing
GenEvolutioN’s cutting-edge approach enhances sensitivity, efficiency, and accuracy through:
- Miniaturization → Use of 96-well plates, reducing cell consumption, medium usage, and test material requirements.
- Fluorescent Labelling → Integration of BMVC staining on Bhas 42 cells, providing higher precision in quantification.
- Transcriptome Analysis → Identification of cell cycle disruptions, including immune response, cell adhesion, apoptosis, and cell proliferation pathways.
A Word from GenEvolutioN’s CEO
“NIAS in food contact materials raise significant health concerns due to their potential migration into food. This innovation is a major step for GenEvolutioN as we continue our mission to become a globally recognized Contract Research Organization (CRO) in in-vitro genotoxicity, dedicated to predicting cancer risks.”
— Isabelle Mouche, Co-founder & CEO, GenEvolutioN
About GenEvolutioN
GenEvolutioN is a specialized Contract Research Organization (CRO) focused on in-vitro genetic toxicology and toxicology expertise, utilizing human cell models and advanced analytical technologies to predict cancer risks and address emerging challenges. Hosted at Seqens’Lab, GenEvolutioN provides GLP-compliant toxicity and genotoxicity testing for the pharmaceutical, cosmetic, medical device, and food industries.
Driven by entrepreneurial spirit and innovation, GenEvolutioN is committed to delivering high-quality research and advisory services while fostering scientific excellence and regulatory compliance.
